Neko Health Secures $700 Million in Funding to Scale Preventive Healthcare Services
Neko Health, a Stockholm-based health tech startup founded by Spotify co-founder Daniel Ek and Swedish entrepreneur Hjalmar Nilsonne, has raised $700 million in a funding round led by Lightspeed Venture Partners and O.G. Venture Partners, according to DealBook. The round values the company at nearly $7 billion, marking a fourfold increase from its January 2025 valuation. The funds will support the company’s expansion into the U.S. market, where it plans to open clinics in New York in the coming months.
Funding Round Attracts High-Profile Investors
The $700 million round includes participation from a mix of venture capital firms and individual investors, including Meta CEO Mark Zuckerberg and his wife, Priscilla Chan; author and investor Tim Ferriss; and French biochemist Jessie Inchauspé, known as the “Glucose Goddess.” Ferriss, who has publicly praised Neko’s approach to health diagnostics, stated in a written statement that the company offers “beautiful simplicity” in delivering “a high-definition map of your biology in less than 60 minutes.”
Investors have been drawn to Neko’s model of offering full-body diagnostic scans and blood tests at a price point of £299 ($400) in the U.K., which the company claims makes preventive healthcare accessible to a broader demographic. As of late 2023, Neko operates eight clinics in Sweden and Britain, with over 350,000 people on its waiting list for scans, though only 100,000 have completed the service, according to the company’s disclosures.
Expanding into Markets with Free Healthcare Systems
Neko’s strategy focuses on entering markets where public healthcare is perceived as free or low-cost, such as the U.K. and Sweden, but where demand for private diagnostic services remains strong. “We’ve gone into markets where health care is free, or perceived to be free, and hundreds of thousands of people line up in a queue for a scan,” Ek said in an interview. This approach has attracted attention from investors who see potential in leveraging consumer demand for personalized health insights.
The company’s technology relies on established diagnostic tools, including MRI scans, to detect early signs of disease. Competitors like Prenuvo and Ezra in the U.S. have also gained traction by offering similar services, often promoted by influencers and celebrities. However, some medical professionals remain skeptical about the clinical utility of whole-body scans, citing concerns about overdiagnosis and unnecessary interventions.
Challenges in Scaling and Medical Scrutiny
Despite its rapid growth, Neko faces challenges in scaling its operations. The company has struggled to process the high volume of demand, with a significant portion of its user base waiting for appointments.
“As health care professionals become more familiar with Neko’s technology, they have sought ways to work more closely with the company,” said Nilsonne. However, the medical community’s acceptance remains a key factor in the startup’s long-term success.
What’s Next for Neko Health?
The latest funding round positions Neko to accelerate its expansion into the U.S. and other markets. The company’s ability to navigate regulatory hurdles, address medical skepticism, and maintain user trust will be critical in determining its impact on the preventive healthcare sector. With a valuation nearing $7 billion, Neko Health’s journey reflects broader trends in the wellness tech industry, where investors are increasingly prioritizing innovations that align with consumer demand for proactive health management.